⌕
ANI Pharmaceuticals · ANIP · Nasdaq
Tenet 69 · Solid
Compare
$70.89−0.77%At closeTenet 69 · Solid
$70.89−0.55 (−0.77%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

ANI Pharmaceuticals (ANIP) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Seeking AlphaNov 7, 2026 · 09:44 ET
ANI Pharmaceuticals, Inc. (ANIP) Q3 2026 Earnings Call Transcript

ANI Pharmaceuticals, Inc. ( ANIP ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Irina Rivkind Koffler - Vice President of Investor Relations Nikhil Lalwani - President, CEO & Director Mary Pao …

● MarketBeatNov 5, 2026 · 13:17 ET
ANI Pharmaceuticals Q3 Earnings Call Highlights

ANI Pharmaceuticals NASDAQ: ANIP reported 28% revenue growth for the third quarter of 2026 and announced an offer to acquire Egetis Therapeutics for $560 million in equity value, while lowering its full-year sales outloo…

● Zacks Investment ResearchNov 5, 2026 · 10:31 ET
ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago a…

● Zacks Investment ResearchNov 5, 2026 · 09:16 ET
ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates

ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.7 per share, beating the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.04 per share a year ago.…

● GlobeNewsWireNov 5, 2026 · 06:51 ETCOMPANY'S OWN WORDS
ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results

PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended September 30, 2026.…

● GlobeNewsWireNov 5, 2026 · 06:50 ET
REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Egetis”) (the “Offer”).…

● GlobeNewsWireNov 5, 2026 · 01:33 ETCOMPANY'S OWN WORDS
ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Egetis”) (the “Offer”).…

● GlobeNewsWireNov 3, 2026 · 06:55 ETCOMPANY'S OWN WORDS
ANI Pharmaceuticals to Present at Upcoming November Investor Conferences

PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Compa…

● GlobeNewsWireOct 23, 2026 · 06:55 ETCOMPANY'S OWN WORDS
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET

PRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results on Thursday, Novembe…

● GlobeNewsWireOct 19, 2026 · 06:55 ETCOMPANY'S OWN WORDS
ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules

PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI's Duloxetine Delaye…

● Defense WorldOct 19, 2026 · 04:22 ET
ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $388,206.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP - Get Free Report) CEO Nikhil Lalwani sold 5,400 shares of the firm's stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $7…

● Zacks Investment ResearchOct 13, 2026 · 13:10 ET
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?

ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.…

● Defense WorldOct 6, 2026 · 08:14 ET
Head to Head Comparison: ANI Pharmaceuticals (NASDAQ:ANIP) and Talphera (NASDAQ:TLPH)

Talphera (NASDAQ: TLPH - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the …

● GlobeNewsWireSep 30, 2026 · 06:55 ETCOMPANY'S OWN WORDS
ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026…

● Zacks Investment ResearchSep 28, 2026 · 12:46 ET
Implied Volatility Surging for ANI Pharmaceuticals Stock Options

Investors need to pay close attention to ANIP stock based on the movements in the options market lately.…

● Seeking AlphaSep 24, 2026 · 12:15 ET
ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The Build

ANI Pharmaceuticals is rated Buy, with a fair value of $104, offering 38% upside from current levels. Generics generate strong EBITDA and cash, funding rare-disease expansion; rare disease is expected to comprise nearly …

● GlobeNewsWireSep 23, 2026 · 06:55 ETCOMPANY'S OWN WORDS
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension

PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its A…

● Seeking AlphaSep 14, 2026 · 10:31 ET
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● Defense WorldSep 11, 2026 · 03:45 ET
Contrasting ANI Pharmaceuticals (NASDAQ:ANIP) and Cumberland Pharmaceuticals (NASDAQ:CPIX)

Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two bus…

● GlobeNewsWireSep 3, 2026 · 06:55 ETCOMPANY'S OWN WORDS
ANI Pharmaceuticals to Present at September Investor Conferences

PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Comp…

● GlobeNewsWireAug 24, 2026 · 06:55 ETCOMPANY'S OWN WORDS
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) tod…

● Defense WorldAug 20, 2026 · 03:18 ET
Aurora Investment Counsel Takes Position in ANI Pharmaceuticals, Inc. $ANIP

Aurora Investment Counsel bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) in a recent quarter, according to its most recent filing with the SEC. The fund bought 26,890 shares of the specialty pharmaceutica…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just ANIP · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.